Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer

Journal of Cancer Research and Therapeutics

Volumn 5, Issue 4, 2009, Pages 272-276

  Mrabti, Hind ^a,b   De La Fouchardiere, Christelle ^a   Desseigne, Francoise ^a   Dussart, Sophie ^a   Negrier, Sylvie ^a   Errihani, Hassan ^b  

^a CENTRE LÉON BÉRARD   (France)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

Cetuximab given every 2 weeks; Metastatic colorectal cancer; Weekly cetuximab

Indexed keywords

CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ACNE; ADULT; AGED; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERITONEUM METASTASIS; REVIEW; SKIN TOXICITY; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77749298347     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.59907     Document Type: Review

References (11)

1. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
3. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
4. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
5. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
7. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
9. Tabernero J, Cervantes A, Martinelli E, Rojo F, Perez-Fidalgo A, Casado E, et al. Optimal dose of cetuximab given every two weeks (q2w): a phase I pharmacokinetic and pharmacodynamic study of weekly (q1w) and q2w schedules in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:142s.
10. Pfeiffer P, Bjerregaard JK, Qvortrup C, Jensen BV, Yilmaz M, Nielsen D. Simplification of cetuximab administration: double dose every second week as a 60 minute infusion. J Clin Oncol 2007;25:4133.
11. Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008;13:113-9.